Skip to main content

Table 3 Associations of clinical characteristics with QTc ≥ 440 ms in combined SLE/RA cohort

From: Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients

Clinical covariates Univariable model QTc ≥ 440 ms Multivariable model QTc ≥ 440 msb
OR 95% CI p OR 95% CI p
Age 1.02 1.00–1.03 0.004 1.00 0.991.02 0.53
Sex 1.29 0.861.96 0.22 ---------- ---------- ----------
Race (white vs non-white) 1.48 1.07–2.03 0.016 1.06 0.681.63 0.80
Disease duration (square root) 0.96 0.861.07 0.48 ---------- ---------- ----------
Current HCQ use 0.48 0.33–0.70 < 0.01 0.77 0.481.23 0.27
Current prednisone use 0.46 0.33–0.64 < 0.01 0.56 0.34–0.92 0.023
Current biologic use 0.83 0.581.19 0.30 ---------- ---------- ----------
Hypertension 1.18 0.871.61 0.29 ---------- ---------- ----------
Current smoking 1.46 0.822.60 0.20 ---------- ---------- ----------
Diabetes 1.64 0.95–2.83 0.076 1.38 0.702.72 0.35
Current statin use 1.08 0.731.60 0.69 ---------- ---------- ----------
Current ASA use 0.51 0.36–0.73 < 0.01 0.68 0.43–1.07 0.095
Any QTc meds 1.07 0.781.47 0.67 ---------- ---------- ----------
Antidepressants 1.79 1.07–2.99 0.027 1.45 0.902.33 0.12
Antipsychotics 1.62 0.624.22 0.33 ---------- ---------- ----------
Antiarrhythmics 1.48 0.435.06 0.53 ---------- ---------- ----------
Muscle relaxants 1.41 0.573.46 0.46 ---------- ---------- ----------
Antimicrobials 0.99 0.621.58 0.97 ---------- ---------- ----------
Antiemetics 1.15 0.632.08 0.65 ---------- ---------- ----------
Anticonvulsants 2.33 0.541.93 0.94 ---------- ---------- ----------
Tacrolimus 1.63 0.723.69 0.24 ---------- ---------- ----------
Ejection fraction % 1.00 0.981.03 0.82 ---------- ---------- ----------
Ejection fraction ≥ 55% 0.81 0.441.49 0.50 ---------- ---------- ----------
Prob > F ---------- 0.0001
  1. Abbreviations: HCQ hydroxychloroquine, QTcMeds QTc prolonging medications
  2. bFinal imputed data